Objetivos
Evaluate real-world progression-free survival
Responsável pelo tratamento
Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Categorias de dados utilizados
Données d’identification (sans donnée nominative) / Données de santé
Origine de données utilisées
Soins
Institut de Cancérologie de l'Ouest (Nantes et Angers)
População sujeita à pesquisa ou ao tratamento de dados
Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib • Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) • Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program) • Patients who were informed about the study and do not object for their data to be collected • Age > 18 years
Base jurídica
Intérêt public
Destinatários internos e externos dos dados
IFCT
Data de início da pesquisa
24/03/2022
Período de retenção de dados
Durée conforme à la réglementation